Arguments in favour of remdesivir for treating SARS-CoV-2 infections
Journal
International Journal of Antimicrobial Agents
Pages
105933
Date Issued
2020
Author(s)
SDGs
Other Subjects
aciclovir; aristeromycin; favipiravir; galidesivir; penciclovir; remdesivir; ribavirin; RNA directed RNA polymerase; adenosine phosphate; alanine; antivirus agent; DNA directed RNA polymerase; remdesivir; amino acid substitution; antibiotic resistance; antiviral activity; clinical effectiveness; concentration response; coronavirus disease 2019; coronavirus disease 2019; Coronavirus infection; drug half life; drug tolerability; Ebola hemorrhagic fever; Editorial; human; nonhuman; priority journal; protein targeting; SARS-related coronavirus; Severe acute respiratory syndrome coronavirus 2; treatment outcome; treatment response; virus load; animal; Betacoronavirus; clinical trial (topic); Coronavirus infection; drug effect; enzymology; pandemic; virus pneumonia; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; DNA-Directed RNA Polymerases; Humans; Pandemics; Pneumonia, Viral
Type
editorial